November 18, 2021

Xcenda is a proud supporter of Virtual ISPOR EU 2021

Join Xcenda at Virtual ISPOR EU 2021 starting on Tuesday, November 30 through Friday, December 3. Meet (virtually) with our commercialization and scientific consultants at this year's event.

For more than 25 years, manufacturers have turned to Xcenda’s leading team of value experts, transforming evidence, policy insights, and market intelligence into effective global market access strategies. Founded in the application of health outcomes and reimbursement, Xcenda, a part of AmerisourceBergen, is a comprehensive global commercialization partner helping clients effectively navigate today’s complex healthcare landscape. Our bench of diverse experts shares a passion to help you deliver the most distinctive body of evidence that demonstrates your value story.

Trust in our committed team of over 700 global associates so you can focus on what matters most—helping patients gain access to your brand.

 

Meeting global needs for our customers
Our Xcenda Germany team comprises of 60+ highly qualified economists, natural scientists, pharmacists, and methodically skilled data analysts who specialize in scientific, contract research, and conducts healthcare-related studies in Germany and Europe. Our team in Germany has expertise in benefit analysis of pharmaceuticals, AMNOG dossiers, pricing, and reimbursement, analysis of primary and secondary research data, health services research, health economic evaluation, as well as scientific communication (publications, workshops, and presentations).

Xcenda also has global team members located in key markets such as the United Kingdom, Switzerland, and Spain, providing our manufacturer customers with global reach and expertise to meet local market access needs.  

Xcenda continues excellence in innovative research

We are proud to present the following research at ISPOR EU 2021 Virtual.

Poster Authors
Cost-Effectiveness of Granulocyte Colony Stimulating Factors (G-CSFS) for the Prevention of Febrile Neutropenia in Breast Cancer Patients Koptelova N, Mehl A, Chaplin S, Maiese B
Economic burden of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency in Europe, from the caregivers’ perspective (PTC Therapeutics Switzerland GmbH, Zug, Switzerland) Solanke O, Martel MJ, Buesch K
Economic burden of informal care and productivity loss due to caring for individuals with aromatic l-amino acid decarboxylase (AADC) deficiency - an analysis for the US (PTC Therapeutics Switzerland GmbH, Zug, Switzerland) Buesch K, Solanke O, Williams K, Skrobanski H, Zhang R, Acaster S, Martel MJ
Health Economic Impact of Phenylketonuria - a Retrospective Claims Database Study in France Okhuoya P, Altevers J, Arnoux JB, Bouée S, Charrière S, Jacob C, Jha A, Maillot F, Schneider KM
Economic Burden of Secondary Hyperparathyroidism in Germany: A Matched Comparison Using Administrative Claims Data Meise D, Schneider KM, Stremel T, Kaiser EA, Soro M
Healthcare Utilization and Costs of Human Papillomavirus (HPV) Associated Anogenital Diseases in Young Women - an Analysis of Statutory  Reuschenbach M, Mihm S, Wölle R, Wähner C, Schneider KM, Jacob C, Greiner W, Hampl M, Goodman E

HTA Quarterly

From at-a-glance updates on important HTA decisions, to reviews that shine a spotlight on what those decisions mean for specific therapeutic areas, each edition of the HTA Quarterly provides insight into the evolving perspectives and priorities for HTAs; as well as Xcenda’s unique perspective so you are more prepared to address the challenges of an uncertain and rapidly changing healthcare environment. Subscribe today

Meet with Xcenda

We’re committed to helping you find solutions to maximize access to your product.  From generating evidence that payers demand to value assessment frameworks consulting, turn to Xcenda for innovative solutions to prove the value of your therapy. 

Meet with Fred Sorenson, Assistant Director, Global Market Access & Support from our European team, to discuss strategies and solutions for your product.